

Title (en)  
GLYPICANS FOR THE DETECTION AND TREATMENT OF HUMAN CARCINOMA

Title (de)  
GLYPICANE ZUR DETEKTION UND BEHANDLUNG HUMANER KARZINOME

Title (fr)  
GLYPICANES SERVANT A DETECTER ET A TRAITER LE CARCINOME HUMAIN

Publication  
**EP 1146903 A4 20050216 (EN)**

Application  
**EP 99954963 A 19991015**

Priority  
• US 9924176 W 19991015  
• US 10451098 P 19981016  
• US 12162499 P 19990225

Abstract (en)  
[origin: WO0023109A1] Glycosylphosphatidylinositol- (GPI-) anchored HSPG glypican-1 is strongly expressed in human breast and pancreatic cancer - both by the cancer cells and in the case of pancreatic cancer the adjacent fibroblasts - whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors: fibroblast growth factor-2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). Treatment of MDA-MB-231 and MDA-MB-468 breast cancer cells with PI-PLC abrogates the mitogenic response to two heparin-binding growth factors, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and fibroblast growth factor-2 (FGF-2). Syndecan-1 is also expressed at high levels in breast cancer tissues as well as breast cancer cells by comparison with breast normal tissues. Temporary or permanent transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. Glypican can be used to detect the carcinoma in vitro and therapeutics that either bind to (e.g., antibodies or drugs), remove (e.g., enzymes) or prevent the expression (e.g., antisense constructs) of surface of the extracellular domain of glypican-1 are effective in retarding the growth of glypican-responsive carcinomas.

IPC 1-7  
**A61K 39/395**; **C07K 16/00**; **C12Q 1/00**; **G01N 33/53**; **G01N 33/567**; **G01N 33/574**

IPC 8 full level  
**A61K 38/46** (2006.01); **A61P 35/00** (2006.01); **C07K 14/47** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01); **G01N 33/574** (2006.01)

CPC (source: EP)  
**A61K 38/465** (2013.01); **A61P 35/00** (2017.12); **C07K 14/4725** (2013.01); **C07K 16/28** (2013.01); **C07K 16/2896** (2013.01); **C07K 16/303** (2013.01); **C12Y 301/04011** (2013.01); **G01N 33/57469** (2013.01); **A61K 2039/505** (2013.01)

Citation (search report)  
• [X] INKI P ET AL: "THE ROLE OF SYNDECAN-1 IN MALIGNANCIES", ANNALS OF MEDICINE, FINNISH MEDICAL SOCIETY DUODECIM, HELSINKI, FI, vol. 28, 1996, pages 63 - 67, XP002927348, ISSN: 0785-3890  
• [X] SEBESTYEN A ET AL: "Expression of Syndecan-1 in Human B Cell Chronic Lymphocytic Leukaemia", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 13, November 1997 (1997-11-01), pages 2273 - 2277, XP004284563, ISSN: 0959-8049  
• See references of WO 0023109A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0023109 A1 20000427**; AU 1118100 A 20000508; AU 769125 B2 20040115; CA 2346264 A1 20000427; EP 1146903 A1 20011024; EP 1146903 A4 20050216

DOCDB simple family (application)  
**US 9924176 W 19991015**; AU 1118100 A 19991015; CA 2346264 A 19991015; EP 99954963 A 19991015